Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Change in Account Payables (2019 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Change in Account Payables for 13 consecutive years, with $4.9 million as the latest value for Q4 2025.

  • Quarterly Change in Account Payables rose 308.79% to $4.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.3 million through Dec 2025, down 66.07% year-over-year, with the annual reading at $5.3 million for FY2025, 66.07% down from the prior year.
  • Change in Account Payables for Q4 2025 was $4.9 million at Madrigal Pharmaceuticals, down from $6.0 million in the prior quarter.
  • The five-year high for Change in Account Payables was $37.0 million in Q3 2024, with the low at -$11.7 million in Q1 2023.
  • Average Change in Account Payables over 5 years is $2.4 million, with a median of $2.4 million recorded in 2021.
  • The sharpest move saw Change in Account Payables soared 5463.49% in 2021, then tumbled 935.93% in 2023.
  • Over 5 years, Change in Account Payables stood at $11.0 million in 2021, then crashed by 51.93% to $5.3 million in 2022, then skyrocketed by 118.24% to $11.5 million in 2023, then crashed by 120.58% to -$2.4 million in 2024, then soared by 308.79% to $4.9 million in 2025.
  • According to Business Quant data, Change in Account Payables over the past three periods came in at $4.9 million, $6.0 million, and -$4.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.